CG Oncology, Inc. Operating Expenses
CG Oncology, Inc. (CGON) reported Operating Expenses of $48.74 million for the 3-month period ending 2025-06-30, per its 10-Q filed 2025-08-08.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2025-08-08
- CG Oncology, Inc. operating expenses for the quarter ending 2025-06-30 was $48.74M, a 87.73% increase year-over-year.
- CG Oncology, Inc. operating expenses for the quarter ending 2025-03-31 was $42.26M, a 83.74% increase year-over-year.
- CG Oncology, Inc. operating expenses for the quarter ending 2024-12-31 was $38.51M, a 98.93% increase year-over-year.
- CG Oncology, Inc. operating expenses for the quarter ending 2024-09-30 was $28.34M, a 101.67% increase year-over-year.
- CG Oncology, Inc. operating expenses for fiscal 2024 was $115.81M, a 108.08% increase from fiscal 2023.
- CG Oncology, Inc. operating expenses for fiscal 2023 was $55.65M.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2025-06-30 | $48.74M 10-Q · filed 2025-08-08 | $91.00M 10-Q · filed 2025-08-08 | $129.50M derived: sum of 3 quarters · filed 2025-08-08 | $157.84M derived: sum of 4 quarters · filed 2025-08-08 |
| 2025-03-31 | $42.26M 10-Q · filed 2025-05-13 | $80.76M derived: sum of 2 quarters · filed 2025-05-13 | $109.10M derived: sum of 3 quarters · filed 2025-05-13 | $135.06M derived: sum of 4 quarters · filed 2025-08-08 |
| 2024-12-31 | $38.51M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | $66.84M derived: sum of 2 quarters · filed 2025-03-28 | $92.81M derived: sum of 3 quarters · filed 2025-08-08 | $115.81M 10-K · filed 2025-03-28 |
| 2024-09-30 | $28.34M 10-Q · filed 2024-11-12 | $54.30M derived: sum of 2 quarters · filed 2025-08-08 | $77.30M 10-Q · filed 2024-11-12 | $96.66M derived: sum of 4 quarters · filed 2025-08-08 |
| 2024-06-30 | $25.96M 10-Q · filed 2025-08-08 | $48.96M 10-Q · filed 2025-08-08 | $68.32M derived: sum of 3 quarters · filed 2025-08-08 | $82.37M derived: sum of 4 quarters · filed 2025-08-08 |
| 2024-03-31 | $23.00M 10-Q · filed 2025-05-13 | $42.35M derived: sum of 2 quarters · filed 2025-05-13 | $56.41M derived: sum of 3 quarters · filed 2025-05-13 | $68.73M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $19.36M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | $33.41M derived: sum of 2 quarters · filed 2025-03-28 | $45.73M derived: sum of 3 quarters · filed 2025-03-28 | $55.65M 10-K · filed 2025-03-28 |
| 2023-09-30 | $14.05M 10-Q · filed 2024-11-12 | $26.38M derived: sum of 2 quarters · filed 2024-11-12 | $36.30M 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $12.33M 10-Q · filed 2024-08-08 | $22.25M 10-Q · filed 2024-08-08 | ||
| 2023-03-31 | $9.91M 10-Q · filed 2024-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |